Literature DB >> 29135121

Hepcidin and iron metabolism in the pathogenesis of prostate cancer.

Feng Wang1, An Liu, Ruyu Bai, Binbin Zhang, Yongsheng Jin, Wei Guo, Yi Li, Jixue Gao, Longqiang Liu.   

Abstract

PURPOSE: To investigate the relationship between Hepcidin and iron metabolism, and cell proliferation, migration, and apoptosis in prostate cancer cells.
METHODS: PC3 prostate cancer cells were cultured in vitro and divided into the control group, Hepcidin overexpression group, and Hepcidin low expression group. Prostate specific antigen (PSA) and soluble transferrin receptor (sTfR) levels were measured by ELISA. The levels of the Hepcidin receptor membrane transporter, Ferroportin, were determined by Western blot. The intracellular iron distribution was determined by immunofluorescence assay. The cell proliferation rate was determined by MTT assay. Cell migration was measured by wound healing assay. Apoptosis was measured by flow cytometry.
RESULTS: Compared with the control group, higher PSA level (p<0.05), lower sTfR level (p<0.05), lower Ferroportin level (p<0.05), lower intracellular iron level (p<0.05), higher cell proliferation and migration rate, and lower apoptotic rate (p<0.05) were found in the Hepcidin overexpression group. The opposite results were found in the Hepcidin low expression group.
CONCLUSIONS: Hepcidin is highly expressed in prostate cancer cells, and can regulate cell proliferation, migration, and apoptosis by increasing intracellular iron transportation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29135121

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  6 in total

1.  An Integrated Systematic Analysis and the Clinical Significance of Hepcidin in Common Malignancies of the Male Genitourinary System.

Authors:  Xiaogang Wang; Qianqian Shi; Pengfeng Gong; Cuixing Zhou; Yunjie Cao
Journal:  Front Genet       Date:  2022-05-12       Impact factor: 4.772

Review 2.  Iron Metabolism in Prostate Cancer; From Basic Science to New Therapeutic Strategies.

Authors:  Driton Vela
Journal:  Front Oncol       Date:  2018-11-27       Impact factor: 6.244

3.  Hepcidin Upregulation in Lung Cancer: A Potential Therapeutic Target Associated With Immune Infiltration.

Authors:  Yumei Fan; Bing Liu; Fei Chen; Zhiyuan Song; Bihui Han; Yanxiu Meng; Jiajie Hou; Pengxiu Cao; Yanzhong Chang; Ke Tan
Journal:  Front Immunol       Date:  2021-04-01       Impact factor: 7.561

4.  Hepcidin is upregulated and is a potential therapeutic target associated with immunity in glioma.

Authors:  Tianyu Dong; Bo Zhang; Runjiao Zhang; Chang Wang; Xiaopeng Liu; Fei Wang; Nana Hao; Ke Tan; Yan-Zhong Chang
Journal:  Front Oncol       Date:  2022-09-27       Impact factor: 5.738

5.  Hepcidin-regulating iron metabolism genes and pancreatic ductal adenocarcinoma: a pathway analysis of genome-wide association studies.

Authors:  Sachelly Julián-Serrano; Fangcheng Yuan; William Wheeler; Beben Benyamin; Mitchell J Machiela; Alan A Arslan; Laura E Beane-Freeman; Paige M Bracci; Eric J Duell; Mengmeng Du; Steven Gallinger; Graham G Giles; Phyllis J Goodman; Charles Kooperberg; Loic Le Marchand; Rachel E Neale; Xiao-Ou Shu; Stephen K Van Den Eeden; Kala Visvanathan; Wei Zheng; Demetrius Albanes; Gabriella Andreotti; Eva Ardanaz; Ana Babic; Sonja I Berndt; Lauren K Brais; Paul Brennan; Bas Bueno-de-Mesquita; Julie E Buring; Stephen J Chanock; Erica J Childs; Charles C Chung; Eleonora Fabiánová; Lenka Foretová; Charles S Fuchs; J Michael Gaziano; Manuel Gentiluomo; Edward L Giovannucci; Michael G Goggins; Thilo Hackert; Patricia Hartge; Manal M Hassan; Ivana Holcátová; Elizabeth A Holly; Rayjean I Hung; Vladimir Janout; Robert C Kurtz; I-Min Lee; Núria Malats; David McKean; Roger L Milne; Christina C Newton; Ann L Oberg; Sandra Perdomo; Ulrike Peters; Miquel Porta; Nathaniel Rothman; Matthias B Schulze; Howard D Sesso; Debra T Silverman; Ian M Thompson; Jean Wactawski-Wende; Elisabete Weiderpass; Nicolas Wenstzensen; Emily White; Lynne R Wilkens; Herbert Yu; Anne Zeleniuch-Jacquotte; Jun Zhong; Peter Kraft; Dounghui Li; Peter T Campbell; Gloria M Petersen; Brian M Wolpin; Harvey A Risch; Laufey T Amundadottir; Alison P Klein; Kai Yu; Rachael Z Stolzenberg-Solomon
Journal:  Am J Clin Nutr       Date:  2021-10-04       Impact factor: 8.472

6.  HAMP Downregulation Contributes to Aggressive Hepatocellular Carcinoma via Mechanism Mediated by Cyclin4-Dependent Kinase-1/STAT3 Pathway.

Authors:  Ying Shen; Xin Li; Yanwei Su; Shaikh Atik Badshah; Bin Zhang; Yanru Xue; Peng Shang
Journal:  Diagnostics (Basel)       Date:  2019-04-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.